Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Intro page might document the 1 for 1500 split that destroyed shareholder value, the history of dilution that destroyed shareholder value, the new and ongoing dilution that is destroying shareholder value, and maybe a widget that simply divides the current pps by 1500 to show the real shareholder value (that was destroyed).
Been a whole week since the last raise, they are about due for another. $1.50 this time?
Looking forward to that animal study required by the FDA on the IND ding list. That is really the only thing on the list that matters and will show this concept has no future. Should have been done 8-10 years ago but KW didn't know what a biotech was and still doesn't. He could use the TD2 data but of course that provides a conclusion he can't retire on.
Seems kind of scammy but I guess since KW didn't call it a scam himself all is on the up and up. I think that must be a BUY SIGNAL lol
If you have been here longer than 2 weeks or so the current pps translates to $0.0022 per share. KW is very good at depreciating stockholder's value. You might even call him a skilled expert at devaluation
Listen to me today; hear me tomorrow. I put the pieces of the puzzle together and let everyone know. You may not understand until later. Good luck and get out ASAP
Most CEOs are vigilant to protect their company and shareholders from naked shorting. KW, the CEO, seeks out "institutional" investors that only fund him if they can naked short. Does that seem odd for a legitimate biotech? Joking because of course everyone should know by now...SCAM
Yes and fine for an individual. A hedge fund has certain additional rules to abide by while shorting in the box. These guys violated at least once in the past while honing their process. They benefit when the price goes down vs their original pps and some might say they desire the price goes down big time to maximize their benefit. They care nothing for the company, its supposed (fake) mission, or other retail investors
These guys have a system of buying big and high and shorting themselves. Not exactly legal and not exactly illegal so a perfect match for KW. They make their own money on their shorts so they could care less about the company or retail. Lots of info on Sabby (shabby) and Intercoastal on the internet. Only ones happy are are the vulture fund investors which attracts a shaddy group of investors
For anyone that cares. More DD to be done that inevitably leads to the same conclusion...scam
https://www.google.com/search?q=Intracoastal+Capital+shorting&oq=i&aqs=chrome.0.69i59l3j69i60l3j69i65j69i60.4347j0j7&sourceid=chrome&ie=UTF-8
Another interesting perspective/opinion on several fronts
I make money no matter the crap stock I invest in. The crappier the better, it is just the way my luck rolls. This has been the crappiest stock I ever invested in (years ago). It is a loser. SCAM
That was a typo in the PR. Should have been institutionalized investors
What's past is prologue. Start the countdown..1...2...3...4.....j....
Yep, that is enough to disappear. Got to imagine the SEC is sniffing around given the shenanigans over the last couple weeks
The pipeline pump is old and stinky from the pmcb sewer many years ago. Note, for diabetes, the Melligen cells originally targeted for encapsulation failed so they currently have no cells for insulin production. For ascites they engaged TD2, a respected CRO, many years ago for pre-clinical work (animal studies). Nothing was every mentioned or published and TD2 dropped the relationship, presumably due to poor or failed tests. GLTA. Do your DD as everything they pump has been tried and failed at least once before.
Better call Roto-Rooter!
There is no memo for common sense
You neglect the reality that "the technology" will never work in the manner the pancreatic cancer trial is envisioned. I have explained that many times here. I inquired to KW/Crab and they don't have any viable explanation other than 'let's just try it'. FDA doesn't believe it either but all they can do is request the pre-clinical work that shows promise to proceed, the animal study (the starting point). Note the prospectus wording about the "hypothetical" mechanism of action. A hypothesis that will never be proven viable (you will never hear that from pmcb) but TD2, the CRO that did pre-clinical work many years ago for pmcb knows and that is why they dropped it and it was never published or pursued. The technology is not viable. This is just a trading play like the slots in Vegas for investors. It is KW's and crony's retirement fund. Good luck, you are going to need it.
KW said in the last conference call it would take about $1.2M to accomplish the FDA ding list to submit the IND. I predict it will take about $60-80M to the point of submission and then when it is rejected again another cash raise will be required lol. Over and Over...
Its a start up now with real funding after 10 years. From the prospectus...In order to address the clinical hold, the FDA has requested that we:
· Conduct an additional nonclinical study in a large animal (such as a pig) to assess the safety, activity and distribution of the drug product candidate;
Essentially prove safety and viability and efficacy with animals. That is how every biotech concept starts. What have they been doing for the last 10 years?
Prediction: If they get past the above and submit a compliant IND (IF) they will need to start with a Phase 1 safety trial the same as every other biotech proceeding through the FDA approval process. This has to be one of the the longest, most expensive biotech startups ever.
GLTA but note, SCAM
Carnival week almost over. Kinda brings a tear to my eye...until next year
That is a proud statement. GLTU
Any long time names here that are "longs" (not traders) have all lost money below a current price of about $90 pps. To be honest... if they understand math and accounting
Don't they have a seat on the board lol? PUMP IT UP
The payout comes just three months after Bristol Myers dished out $50 million upfront in a deal that could reach $1.2 billion https://t.co/wTvksNMXR2
— FierceBiotech (@FierceBiotech) August 18, 2021
They have no data relevant to FDA requirements. They did nothing to advance the technology in the past 8 years. They are essentially a startup with an idea
You get half a point for trying. That is vendor information and guess what they are trying to sell...cell in a box. I might call them marketing (not sales).
Incorrect statement for US FDA standards. Once you understand and accept that you realize this is a startup enterprise
Another +1M was added to the float with the recent financing. And then there are the warrants that added another +1M potentially. Get used to it, this is how the KW flimflam man rolls
Why experiment on humans when most if not all these questions could be answered with pre-clinical work? I think the FDA thinks the same. GLTU
So every new "investor" in the know dumped both their shares and warrants on Friday above $4.25? Kind of a two for one sale.
The pancreatic cancer technology application will never work. It is common sense given some basic understanding of the prodrug ifex, the circulatory system, and the human liver. Not any published pre-clincal work has been done by pmcb with the technology. I say "published" because TD2, a respected CRO, conducted pre-clinical work with the involvement of Dr. Von Hoff. He and the organization dropped it like a hot potato. It is up to investors to speculate why that happened and no further technical work was subsequently conducted. Bavarian Nordic dropped it many years prior. Do your own DD, I did.
SESN no go
Gap at $2.40? Come on back
I would think there are some unhappy investors that participated in that raise. NASDAQ can't be thrilled with how they were used to facilitate this scam investment. Maybe there will be more legal oversight since they are dealing with a different class of investors and riding on the NASDAQ reputation. For now the scam continues and KW's retirement is secure.
In the last conference call KW said he needed $1.2M to get to the point of submitting the IND. Let's see how much he squanders
When it comes to investing in a biotech company, management is one of (if not the) most important part to consider
Its even a better deal, the offering is at $4.25 per share. But wait....there's more! That $4.25 gets you not only one valuable $2.86 share but also a full warrant for another share with an exercise price of $4.25 per share. Double your pleasure and pain. The old razzmatazz from the flimflam man and CEO, KW himself. Lots of strategery and higher order financial thinking went into this retirement plan
I was dumping as many as I could as fast as I could pre-split at .013, a pathetic price for any long. BTW that equates to about $20 per share in today's economics. Seems like that was only a month ago
Essentially they are starting from ground zero with no published pre-clinical data generated yet as requested by the FDA (pig study). They have about $2M and are seeking funds (via dilution) to test the concept and submit an IND. Management is shaky at best. Shady seems a better description. Seems like a risky startup
Are we tired of winning here yet?
Buying opportunity this morning...again. Let's hear that flawed argument how pps doesn't matter.
per KW on the conference call the cost to do all those things to submit the IND is $1.2M